Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 19;11(4):76.
doi: 10.1038/s41408-021-00468-6.

Germline variants at SOHLH2 influence multiple myeloma risk

Affiliations

Germline variants at SOHLH2 influence multiple myeloma risk

Laura Duran-Lozano et al. Blood Cancer J. .

Erratum in

  • Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk.
    Duran-Lozano L, Thorleifsson G, Lopez de Lapuente Portilla A, Niroula A, Went M, Thodberg M, Pertesi M, Ajore R, Cafaro C, Olason PI, Stefansdottir L, Bragi Walters G, Halldorsson GH, Turesson I, Kaiser MF, Weinhold N, Abildgaard N, Andersen NF, Mellqvist UH, Waage A, Juul-Vangsted A, Thorsteinsdottir U, Hansson M, Houlston R, Rafnar T, Stefansson K, Nilsson B. Duran-Lozano L, et al. Blood Cancer J. 2021 Nov 16;11(11):181. doi: 10.1038/s41408-021-00575-4. Blood Cancer J. 2021. PMID: 34782614 Free PMC article. No abstract available.

Abstract

Multiple myeloma (MM) is caused by the uncontrolled, clonal expansion of plasma cells. While there is epidemiological evidence for inherited susceptibility, the molecular basis remains incompletely understood. We report a genome-wide association study totalling 5,320 cases and 422,289 controls from four Nordic populations, and find a novel MM risk variant at SOHLH2 at 13q13.3 (risk allele frequency = 3.5%; odds ratio = 1.38; P = 2.2 × 10-14). This gene encodes a transcription factor involved in gametogenesis that is normally only weakly expressed in plasma cells. The association is represented by 14 variants in linkage disequilibrium. Among these, rs75712673 maps to a genomic region with open chromatin in plasma cells, and upregulates SOHLH2 in this cell type. Moreover, rs75712673 influences transcriptional activity in luciferase assays, and shows a chromatin looping interaction with the SOHLH2 promoter. Our work provides novel insight into MM susceptibility.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests. Authors G.T., P.U., L.S., G.B.W., G.H., U.T., T.R., and K.S. are employed by deCODE Genetics/Amgen.

Figures

Fig. 1
Fig. 1. Region plots of the 13q13.3 association.
a −log10(P) for association in the meta-analysis of the four Nordic discovery sets (y-axis). The colour reflects the extent of LD with the 13q13.3 lead variant rs200203825. b Genes mapping to the region of association, based on NCBI build 38 of the human genome. c Chromatin looping interaction between rs75712673 and the SOHLH2 promoter, detected in promoter-capture HiC in transformed fibroblasts, data from GeneHancer d ATAC-seq chromatin accessibility across primary blood cell types; rs75712673 maps to a region that is selectively open in plasma cells. e Chromatin immunoprecipitation and sequencing (ChIP-seq) data for H3K4me3 histone mark in L363 MM plasma cell line.
Fig. 2
Fig. 2. Candidate variant rs75712673 eQTL effect on SOHLH2.
a Correlation of genotype and log transformed RNA-seq data from CD138 + plasma cell isolated from the bone marrow of 188 MM patients (Wilcoxon p = 0.0081). b Luciferase activity of rs75712673 reference and alternative alleles in two MM cell lines, L363 (t-test p = 0.0284) and OPM2 (t-test p = 0.0068) shows that regulation of SOHLH2 expression varies in the two alleles of rs75712673. Error bars indicate standard deviation.

Similar articles

Cited by

  • A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk.
    Dicanio M, Giaccherini M, Clay-Gilmour A, Macauda A, Sainz J, Machiela MJ, Rybicka-Ramos M, Norman AD, Tyczyńska A, Chanock SJ, Barington T, Kumar SK, Bhatti P, Cozen W, Brown EE, Suska A, Haastrup EK, Orlowski RZ, Dudziński M, Garcia-Sanz R, Kruszewski M, Martinez-Lopez J, Beider K, Iskierka-Jazdzewska E, Pelosini M, Berndt SI, Raźny M, Jamroziak K, Rajkumar SV, Jurczyszyn A, Vangsted AJ, Collado PG, Vogel U, Hofmann JN, Petrini M, Butrym A, Slager SL, Ziv E, Subocz E, Giles GG, Andersen NF, Mazur G, Watek M, Lesueur F, Hildebrandt MAT, Zawirska D, Ebbesen LH, Marques H, Gemignani F, Dumontet C, Várkonyi J, Buda G, Nagler A, Druzd-Sitek A, Wu X, Kadar K, Camp NJ, Grzasko N, Waller RG, Vachon C, Canzian F, Campa D. Dicanio M, et al. Int J Cancer. 2023 Jan 15;152(2):239-248. doi: 10.1002/ijc.34278. Epub 2022 Oct 1. Int J Cancer. 2023. PMID: 36082445 Free PMC article.
  • Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma.
    Husby S, Tulstrup M, Harsløf M, Nielsen C, Haastrup E, Ebbesen LH, Klarskov Andersen M, Pertesi M, Brieghel C, Niemann CU, Nilsson B, Szabo AG, Andersen NF, Abildgaard N, Vangsted A, Grønbæk K. Husby S, et al. Leukemia. 2024 Nov;38(11):2456-2465. doi: 10.1038/s41375-024-02396-3. Epub 2024 Sep 2. Leukemia. 2024. PMID: 39223296 Free PMC article.
  • SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.
    Chu E, Wu J, Kang SS, Kang Y. Chu E, et al. Curr Oncol. 2023 Aug 27;30(9):7891-7903. doi: 10.3390/curroncol30090573. Curr Oncol. 2023. PMID: 37754488 Free PMC article. Review.
  • FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk.
    Bodnar S, Brander T, Gold J, Iverson A, Lagana A, Onel K, Jagannath S, Parekh S, Thibaud S. Bodnar S, et al. Semin Hematol. 2025 Feb;62(1):11-19. doi: 10.1053/j.seminhematol.2024.11.006. Epub 2024 Nov 30. Semin Hematol. 2025. PMID: 39721861 Review.
  • Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6.
    Clay-Gilmour A, Chattopadhyay S, Hildebrandt MAT, Thomsen H, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Manasanch EE, Norman A, Kumar S, Rajkumar SV, Slager S, Försti A, Vachon CM, Hemminki K. Clay-Gilmour A, et al. Blood Cancer J. 2022 Apr 13;12(4):60. doi: 10.1038/s41408-022-00658-w. Blood Cancer J. 2022. PMID: 35418122 Free PMC article. No abstract available.

References

    1. Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548. - PubMed
    1. Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood. 2012;119:5359–5366. - PMC - PubMed
    1. González-Calle V, Mateos MV. Monoclonal gammopathies of unknown significance and smoldering myeloma: assessment and management of the elderly patients. Eur. J. Intern. Med. 2018;58:57–63. - PubMed
    1. Kyle RA, et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 2006;354:1362–1369. - PubMed
    1. Mouhieddine TH, Weeks LD, Ghobrial IM. Monoclonal gammopathy of undetermined significance. Blood. 2019;133:2484–2494. - PubMed

Publication types

Substances